07:49 AM EDT, 08/16/2024 (MT Newswires) -- Pfizer ( PFE ) and BioNTech (BNTX) said Friday that results from their phase 3 study assessing a combined mRNA vaccine candidate targeting both influenza and COVID-19 in healthy adults met its primary immunogenicity targets.

The trial, which involved over 8,000 participants 18 to 64 years of age, aimed to assess the safety, tolerability, and immunogenicity of a single-dose combination vaccine candidate versus a licensed influenza vaccine and their licensed COVID-19 vaccine given at the same visit, the companies said.

The formulation showed "higher influenza A responses versus a licensed influenza vaccine" and "comparable responses" against SARS-CoV-2 compared with the companies' licensed COVID-19 vaccine, they added.

Pfizer's ( PFE ) phase 2 trial of a second-generation mRNA-based influenza vaccine also demonstrated "robust immunogenicity" against both influenza and COVID-19 and no safety signals were identified, according to the companies' joint release.

Price: 28.74, Change: +0.03, Percent Change: +0.10